Your browser is no longer supported. Please, upgrade your browser.
Settings
VRCA Verrica Pharmaceuticals Inc. daily Stock Chart
VRCA [NASD]
Verrica Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own48.92% Shs Outstand24.96M Perf Week-7.43%
Market Cap176.45M Forward P/E- EPS next Y-1.97 Insider Trans0.00% Shs Float9.85M Perf Month-37.09%
Income-30.60M PEG- EPS next Q-0.45 Inst Own35.10% Short Float10.60% Perf Quarter-37.27%
Sales- P/S- EPS this Y-41.60% Inst Trans0.55% Short Ratio9.20 Perf Half Y-56.42%
Book/sh2.27 P/B2.85 EPS next Y-11.90% ROA-38.20% Target Price- Perf Year-38.52%
Cash/sh3.25 P/C2.00 EPS next 5Y- ROE-45.20% 52W Range6.30 - 18.67 Perf YTD-59.22%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-65.29% Beta-
Dividend %- Quick Ratio27.50 Sales past 5Y- Gross Margin- 52W Low2.86% ATR0.87
Employees17 Current Ratio27.50 Sales Q/Q- Oper. Margin- RSI (14)31.96 Volatility8.05% 9.83%
OptionableNo Debt/Eq0.61 EPS Q/Q-30.80% Profit Margin- Rel Volume1.73 Prev Close6.56
ShortableYes LT Debt/Eq0.61 Earnings- Payout- Avg Volume113.53K Price6.48
Recom2.00 SMA20-18.94% SMA50-39.11% SMA200-48.32% Volume196,058 Change-1.22%
Jul-15-20Downgrade BofA Securities Buy → Neutral
Jun-30-20Reiterated H.C. Wainwright Buy $24 → $18
Jun-24-20Initiated Northland Capital Outperform $21
Mar-24-20Initiated Needham Buy $20
Feb-21-19Initiated H.C. Wainwright Buy $20
Aug-03-20 05:35PM  
12:00PM  
Aug-02-20 12:45PM  
Aug-01-20 07:10PM  
Jul-31-20 01:35PM  
Jul-30-20 12:00PM  
11:30AM  
Jul-29-20 10:40PM  
12:23PM  
Jul-25-20 02:34PM  
Jul-24-20 01:00PM  
Jul-23-20 11:15AM  
07:31AM  
07:30AM  
Jul-22-20 07:55PM  
01:00PM  
11:00AM  
Jul-21-20 02:40PM  
12:00PM  
09:42AM  
Jul-20-20 01:30PM  
12:00PM  
11:14AM  
09:34AM  
08:00AM  
Jul-18-20 03:40PM  
Jul-17-20 01:40PM  
12:50PM  
12:42PM  
12:00PM  
Jul-16-20 01:58PM  
01:36PM  
11:00AM  
09:18AM  
Jul-15-20 11:05PM  
08:35PM  
07:00PM  
02:29PM  
12:00PM  
Jul-14-20 11:40PM  
07:01PM  
06:45PM  
05:00PM  
03:26PM  
02:29PM  
02:08PM  
07:00AM  
Jul-13-20 08:47AM  
Jul-09-20 11:01PM  
10:00AM  
Jul-08-20 02:00PM  
Jul-07-20 04:29PM  
Jul-06-20 07:26PM  
03:15PM  
Jul-02-20 11:00AM  
Jul-01-20 10:39PM  
03:45PM  
Jun-30-20 06:00PM  
04:00PM  
02:19PM  
07:41AM  
Jun-29-20 04:05PM  
Jun-12-20 10:00AM  
Jun-10-20 07:30AM  
May-27-20 05:19PM  
07:30AM  
May-07-20 07:00AM  
May-06-20 07:05AM  
Apr-09-20 04:05PM  
Mar-13-20 07:00AM  
Mar-11-20 07:00AM  
Feb-20-20 09:45AM  
Jan-29-20 07:00AM  
Jan-18-20 10:00AM  
Jan-08-20 11:16AM  
Nov-28-19 10:43PM  
Nov-27-19 07:00AM  
Nov-25-19 07:00AM  
Nov-19-19 07:00AM  
Nov-06-19 04:05PM  
Nov-01-19 12:56PM  
Oct-18-19 07:00AM  
Oct-09-19 07:00AM  
Oct-07-19 07:00AM  
Sep-27-19 11:03AM  
Sep-24-19 09:17AM  
Sep-20-19 11:54AM  
Sep-18-19 09:31AM  
Sep-16-19 07:00AM  
Sep-11-19 10:13AM  
Aug-28-19 01:34PM  
07:00AM  
Jun-27-19 04:01PM  
07:26AM  
Jun-26-19 04:01PM  
May-28-19 09:41AM  
May-21-19 07:00AM  
May-07-19 04:01PM  
May-01-19 07:47AM  
Mar-07-19 04:01PM  
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.